Sign in

Joaquin Duato

Chairman of the Board and CEO at JOHNSON & JOHNSON
Board
Since January 3, 2022
Age
61 years
Education
Holds an MBA from ESADE in Barcelona, Spain and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona.
Tenure
Joined the company in 1989 and advanced through multiple leadership roles—including positions as Worldwide Chairman of Pharmaceuticals, Executive Vice President, and Vice Chairman—before becoming CEO on January 03, 2022 and Chairman on January 02, 2023.

Also at JOHNSON & JOHNSON

EF
Elizabeth Forminard
EVP, General Counsel
JS
James Swanson
EVP, Chief Information Officer
JLT
Jennifer L. Taubert
EVP, Worldwide Chairman, Innovative Medicine

About

Joaquin Duato is a globally minded leader known for his dual citizenship in Spain and the United States, which has enriched his international perspective and commitment to diverse viewpoints. His personal approach is deeply rooted in the company’s Credo values, emphasizing patient care, employee well-being, and community responsibility.

Throughout a distinguished career spanning over 35 years at the organization, he has consistently taken on roles of escalating responsibility. His career highlights include key positions in the Pharmaceuticals sector, where he provided strategic guidance and operational leadership during his tenure as Worldwide Chairman, Executive Vice President, and Vice Chairman.

Under his visionary leadership, the strategic direction of the company has been refined with an unwavering focus on innovative medicine and MedTech solutions. His efforts have been pivotal in expanding the pipeline of therapies in critical areas such as oncology, immunology, neuroscience, and pulmonary hypertension, reinforcing his reputation as a purpose-driven executive.

$JNJ Performance Under Joaquin Duato

Past Roles

OrganizationRoleDate RangeDetails
Hess CorporationDirector2019 - 2022Former external board role
Johnson & JohnsonVice Chairman of the Executive CommitteeJuly 2018 - 2022?Provided strategic direction for Pharmaceutical and Consumer Health sectors, supply chain, IT, global services, and Health & Wellness groups
Johnson & JohnsonExecutive Vice President, Worldwide Chairman, Pharmaceuticals2016
Johnson & JohnsonMember of the Executive Committee2016
Johnson & JohnsonWorldwide Chairman, Pharmaceuticals2011
Johnson & JohnsonCompany Group Chairman, Pharmaceuticals2009

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $1,584,615AnnualFixed base pay.
Registrant Contributions to Defined Contribution Plans $71,308AnnualContribution to defined contribution plans.
Insurance Premiums $0AnnualNo insurance premium expense.
Perquisites and Other Personal Benefits $170,684AnnualIncludes $145,685 for personal use of corporate aircraft and personal use of a company car and driver.

Performance Compensation

Data from  FY 2023

Annual Incentive Payout

Metric (Unit, scale)Value with Citation
Threshold (USD) $0
Target (USD) $2,800,000
Maximum (USD) $5,600,000
Actual Payout (USD) $3,650,000
Financial Goals Weight (%) 70%
Strategic Goals Weight (%) 30%
Enterprise Financial Payout Factor (%) 130.5%
Enterprise Strategic Payout Factor (%) 130.0%
Overall Payout Factor (%) 130.4%
Performance Period Calendar Year 2023
Payout Timing Q1 2024

Long-Term Incentives (LTIs)

Component (Unit, scale)Details
PSUs Grant Date: Feb 13, 2023; Vesting Schedule: 3-year period with 0% to 200% outcome; Performance Metrics: EPS (50% weight) and Relative TSR (50% weight); Grant Date Fair Value: Target $9,335,592 and Maximum $18,671,185.
RSUs Grant Date: Feb 13, 2023; Vesting Schedule: One-third vests per anniversary over 3 years; Grant Date Fair Value: $1,599,051.
Options Grant Date: Feb 13, 2023; Vesting Schedule: One-third per year with a 10-year term; Exercise/Base Price: $162.75 per share; Grant Date Fair Value: $4,796,990.

Annual Performance Bonus

Metric (Unit, scale)Details
Performance MetricsBased on combined financial (70% weight) and strategic (30% weight) goals.
Overall Payout Factor 130.4% of target, with a payout range from 0% to 200% of the target award.
Evaluation & VestingAligned with the performance review of the Annual Incentive Payout; evaluated for the calendar year 2023 with cash-based award mechanics.

This comprehensive performance compensation structure for 2023 includes multiple components with clearly defined metrics, targets, vesting schedules, and actual outcomes as detailed above.

Interviews

Johnson & Johnson CEO: Our aim is to become the number one oncology company thumbnail

Johnson & Johnson CEO: Our aim is to become the number one oncology company

CNBC Television
7:32 min
Jun 3, 2024
J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook thumbnail

J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook

CNBC Television
9:48 min
Dec 5, 2023
Johnson & Johnson CEO Discusses Branding and Leadership thumbnail

Johnson & Johnson CEO Discusses Branding and Leadership

Steve Adubato
14:18 min
Oct 12, 2023
USAIC's Fireside Chat with Joaquin Duato, Chairman & CEO, Johnson & Johnson thumbnail

USAIC's Fireside Chat with Joaquin Duato, Chairman & CEO, Johnson & Johnson

USAIC
41:20 min
Jan 15, 2024
Servant leadership and the builder mindset | A conversation with Joaquín Duato | Do Better Talks thumbnail

Servant leadership and the builder mindset | A conversation with Joaquín Duato | Do Better Talks

Esade
7:30 min
Jun 3, 2024
Cultura corporativa y desarrollo profesional | Conversación con Joaquín Duato | Do Better Talks thumbnail

Cultura corporativa y desarrollo profesional | Conversación con Joaquín Duato | Do Better Talks

Esade
7:06 min
Jun 3, 2024
Lessons in Leadership: Rakia Reynolds and Joaquin Duato thumbnail

Lessons in Leadership: Rakia Reynolds and Joaquin Duato

Steve Adubato
30:00 min
Oct 24, 2023
U.S. Rep. Mikie Sherrill (D) - NJ;  Joaquin Duato thumbnail

U.S. Rep. Mikie Sherrill (D) - NJ; Joaquin Duato

Steve Adubato
30:01 min
Oct 16, 2023